logo-loader
viewShield Therapeutics PLC

Additional Listing

/**/ sup{font-size:80%}link{ color: blue }visited{ color: #954F72 } .bz{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 49.65pt 72.0pt;}div.bz{}p.db{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: 23.5pt; margin-top: 0cm; text-align: center}span.cz{color:black}p.dc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: 23.45pt; margin-top: 0cm; text-align: center}p.dd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: 23.45pt; margin-top: 0cm; text-align: center}p.de{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: justify}p.df{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}p.dg{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}p.dh{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center} p.di{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}table.dj{margin-left:-16.2pt;border-collapse:collapse}td.cq{width:202.65pt;padding:0cm 5.4pt 0cm 5.4pt}td.co{width:237.85pt;padding:0cm 5.4pt 0cm 5.4pt}p.dk{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right}p.dl{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}span.cm{font-size:12.0pt; font-family:"Times New Roman","serif"}span.cl{font-size:12.0pt;font-family:"Times New Roman","serif"}p.dm{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; font-weight: bold; line-height: normal; margin-bottom: 0cm}span.cj{background:white} span.ch{color:black;border:none windowtext 1.0pt; padding:0cm}p.dn{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.do{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.dp{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.dq{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.bp{}span.cd{font-size: 9.0pt;font-family:"Calibri","sans-serif";color:black}span.cc{font-size:11.0pt; font-family:"Calibri","sans-serif"}span.dr{font-size:11.0pt; font-family:"Calibri","sans-serif";color:#1F497D}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";} /**/
RNS Number : 2256E
Shield Therapeutics PLC
02 July 2019
 

Shield Therapeutics plc

("Shield" or the "Group")

 

Additional Listing

 

London, UK, 2nd July 2019: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that it issued and allotted 100,000 Ordinary Shares of 1.5p each following the exercise of options under the Shield Therapeutics Retention and Performance Share Plan.

 

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 8th July 2019. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

 

Following admission, the Company's issued share capital will comprise 117,188,657 ordinary Shares and each Ordinary Share carries one vote. There are no Ordinary Shares held in treasury and accordingly, the total number of voting rights is 117,188,657. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

- Ends -

 

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Carl Sterritt, Chief Executive Officer

+44 (0)20 7186 8500

Tim Watts, Chief Financial Officer

 

 

 

 

Nominated Advisor and Broker

 

Peel Hunt LLP

 

James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

 

Joint Broker

finnCap Ltd     

Geoff Nash/Matt Radley/Alice Lane                                             

 

 

+44 (0)20 7220 0500

 

 

 

Financial PR & IR Advisor

 

Walbrook PR

+44 (0)20 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

+44 (0)7980 541 893 / +44 (0)7584 391 303

 

 

 

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs.  The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.  Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.  For more information please visit www.shieldtherapeutics.com. 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ALSKMGGNGZVGLZM

Quick facts: Shield Therapeutics PLC

Price: 184.5

Market: LSE
Market Cap: £216.21 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics: Analyst discusses further positive data from...

Proactive Research analyst Emma Ulker discusses further positive data which has been released from Shield Therapeutics' (LON:STX) non-inferiority AEGIS H2H study. It pitted Shield's oral ferric maltol (branded as Feraccru in Europe and Accrufer in US) against intravenous ferric carboxymaltose...

3 weeks, 2 days ago